RHHBY - Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer | Benzinga
Friday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with chemoradiotherapy (CRT) for FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer.
The approval is based on data from the Phase 3 KEYNOTE-A18 trial, in which Keytruda plus CRT demonstrated an improvement in progression-free survival (PFS), reducing the risk of disease progression or death by 41% compared to placebo plus CRT.
The trial enrolled 1,060 patients with cervical cancer who had not previously received ...